Juturna Bio raises CHF 50,000

Juturna Bio, an EPFL spin-off based at the Campus Biotech, is developing epigenetic therapies to restore the function of ageing brain cells, with Alzheimer's as the first target. A CHF 50,000 FIF grant funds a translational proof of concept.

Announced on
Round
Grant
Amount
CHF 50,000
Location
Geneva
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic